United Therapeutics (UTHR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $7.27
- Estimate
- $6.86
- Surprise
- +6.0%
- Revenue (period 2026-06-30)
- $783.3M
- Score at report (before → after)
- 5.2 → 5.2/10
Revenue source: xbrl.
How the report landed
United Therapeutics (UTHR) beat the $6.86 estimate with adjusted EPS of $7.27 — a clear 6.0% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.2/10) to Sell at 5.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates UTHR Hold at 5.0/10.
3 of the last 4 quarters beat the estimate; this quarter's +6.0% surprise compares with a +1.9% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%)
- Concentration risk — Customer: Accredo and CVS Specialty
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $593.72
- Stop
- $561.84
At 21.0× trailing and 19.3× forward earnings, consensus estimates imply little change in earnings power.
Risk check: RSI 74 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
UTHR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $25.15B
- P/E (fwd)
- 19.3
- P/E (ttm)
- 21.0
- 52-week range
- $415.26–$609.35
- Off 52-week high
- 2.6%
- RSI (14)
- 74
- Volume vs avg
- 0.01×
- Score today
- 5.0/10